Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal CancerMay 16th 2019
A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.
Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal CancerJanuary 26th 2019
Pembrolizumab (Keytruda) was found to reduce the risk of death by 31% in patients with PD-L1–positive (combined positive score [CPS] ≥10) advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy, according to phase III findings of the KEYNOTE-181 trial.
Nivolumab Extends Survival in Advanced or Recurrent Esophageal CancerJanuary 18th 2019
Nivolumab (Opdivo) significantly improved overall survival (OS) versus chemotherapy in patients with unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine plus platinum-based therapy, according to topline findings of the phase III ATTRACTION-3 study.
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid TumorsApril 20th 2018
BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
Oncology Found Her: Going the Extra Mile for Patients With Head and Neck CancerJune 24th 2017
Sara Sargente found her calling at age 13, caring for her grandfather who had cancer. This oncology nurse navigator and winner of CURE® magazine's 2017 Extraordinary Healer® Award has never looked back.
Treatment Informed by PET Imaging Linked to Better Response Rates in Esophageal CancerJanuary 18th 2017
Patients with esophogeal cancers who received induction chemotherapy, followed by PET imaging to determine whether alternative chemotherapy was needed had improved pathologic complete response rates
Complete Responses With Reduced-Dose Radiation in HPV-Linked Oropharynx CancersJanuary 10th 2017
For patients with HPV-related oropharyngeal squamous cell carcinoma, induction chemotherapy plus reduced-dose radiation and weekly cetuximab brought improvements for swallowing and nutritional status along with complete clinical responses.
Oral HPV Test Shows Potential for Predicting Oropharyngeal Cancer RiskJanuary 30th 2016
Individuals with detectable human papillomavirus (HPV)-16 in their mouthwash samples were 22 times more likely to develop oropharyngeal cancer (OPC) than those without the type of virus, according to findings of a new study.
HPV Vaccination in Boys Found Cost-Effective in Preventing Oropharyngeal CancerApril 17th 2015
A new study has shown that vaccinating adolescent boys may be cost-effective for preventing oropharyngeal cancer, a disease that's projected to become the most common HPV-related cancer by 2020.